Antibe Therapeutics Inc (CVE:ATE) insider David James Vaughan bought 55,000 shares of Antibe Therapeutics stock in a transaction dated Wednesday, October 10th. The stock was acquired at an average cost of C$0.34 per share, with a total value of C$18,700.00.
Shares of CVE:ATE opened at C$0.30 on Friday. Antibe Therapeutics Inc has a one year low of C$0.08 and a one year high of C$0.79.
Antibe Therapeutics (CVE:ATE) last announced its earnings results on Wednesday, August 29th. The company reported C($0.01) EPS for the quarter, beating analysts’ consensus estimates of C($0.02) by C$0.01. Antibe Therapeutics had a negative net margin of 94.01% and a negative return on equity of 130.60%. The business had revenue of C$2.54 million during the quarter, compared to analysts’ expectations of C$2.30 million.
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.
Further Reading: Asset Allocation and Your Retirement
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.